Format

Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2014 Mar;28(3):621-8. doi: 10.1038/leu.2013.330. Epub 2013 Nov 6.

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Author information

1
Department of Hematology, Università degli Studi di Firenze, AOU Careggi, Florence, Italy.
2
German Cancer Research Center, Genomic Epidemiology Group, Heidelberg, Germany.
3
Department of Clinical and Biological Sciences, Università di Torino, Turin, Italy.
4
Department of Hematology, Università Cattolica S. Cuore, Rome, Italy.
5
1] Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Biologique, Hôpitaux Universitaires Paris Centre, Paris, France [2] Département Développement, Reproduction et Cancer, Institut Cochin, INSERM U1016, CNRS UMR8104 and Université Paris Descartes, Paris, France.

Abstract

The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30-40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the utility of this therapy. We determined the expression levels of genes involved in AZA metabolism: UCK1, UCK2, DCK, hENT1, RRM1 and RRM2 using quantitative PCR in samples from 57 patients with MDS who received AZA. Lower expression of UCK1 was seen in patients without a response to AZA (median 0.2 vs 0.49 for patients with response to AZA, P=0.07). This difference in UCK1 expression was not influenced by aberrant methylation of the UCK1 promoter. In addition, the seven polymorphic loci found in the coding sequence were not associated with UCK1 gene expression nor AZA response. Silencing of UCK1 by siRNA leads to blunted response to AZA in vitro. The univariate analysis revealed that patients expressing lower than median levels of UCK1 had a shorter overall survival (P=0.049). Our results suggest that expression level of UCK1 is correlated with clinical outcome and may influence the clinical response to AZA treatment in patients with MDS.

PMID:
24192812
PMCID:
PMC3948159
DOI:
10.1038/leu.2013.330
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center